Denmark sets a new EU benchmark for clinical trial timelines
Denmark sets a new EU benchmark for clinical trial timelines

insight

Denmark sets a new EU benchmark for clinical trial timelines

insight

Denmark sets a new EU benchmark for clinical trial timelines

Denmark has cut Phase I clinical trial approval times to just 14 days – the fastest in Europe. This step cements Denmark’s role as a life science leader, attracting more global pharmaceutical and biotech companies to test and launch treatments here first.

When

With the Strategy for Life Science towards 2030 (New Danish life science strategy), published in November 2024, the Danish government committed to establishing a fourth Medical Research Ethics Committee. The goal? To ensure Phase 1 trials are processed within just 14 days, reinforcing Denmark’s position as one of the most attractive locations in Europe to conducting clinical trials.

On 14. august 2025, the new 14-day assessment process for phase I trials was officially launched. It includes concurrent regulatory and ethics assessments of applications, a collaboration between the Danish Medicines Agency (DMA) and the Danish Medical Research Ethics Committees (MREC).

Initially, the fast-track timeline will automatically apply to all mono-national phase I and phase I-II trials. For multinational trials, accelerated approval will depend on other Member States matching Denmark’s speed. The DMA and MREC encourage other countries to adapt similar rapid assessment models, improving Europe’s competitiveness as a whole. 

“The Danish model proves that regulatory innovation is a competitive edge. Tight timelines reveal systemic strength in the Danish system. Only efficient systems can deliver at speed. Sponsors recognize that rapid timelines mean broader capabilities beyond mere processing speed. By guaranteeing 14-day approvals, we invite sponsors to push other EU countries to match us. It’ll make all of Europe more competitive, not just Denmark.”

Helle Harder

Head of Science & Ethics Division, The Danish National Centre for Ethics

Helle Harder, Head of Science & Ethics Division, The Danish National Centre for Ethics

Want to know more the new 14 days approval time?

Denmark consistently ranks among Europe’s top countries for the number of clinical trials per capita (see table below). With the new fast-track review process for, Denmark will now be twice as fast as the standard timelines in the EU and the UK.

Number of clinical drug trials per mio. capita in top 10 European countries 2025
“Clinical trials are crucial for the Danish patients and our healthcare system, they bring new knowledge, innovation and treatment options, all to the benefit of the patients. At Invest in Denmark, we actively work to attract more clinical trials to Denmark, and we’re seeing a growing number of the world’s leading life science companies choose Denmark. With the new 14-day assessment time, I am confident this growth will continue.“

Vanessa Vega Saenz

Director, Invest in Denmark, Ministry of Foreign Affairs of Denmark 

Why this matters for investors?

Get new knowledge

Download fact sheet on clinical trials in Denmark?

Where do you go to conduct the clinical trials that your business depends on? For a growing number of the world’s major life science companies, the answer is Denmark. Let us provide you with a short introduction to the reasons why Denmark is such a great location in this fact sheet.

get in touch

Invest in Denmark provides free-of-charge confidential and tailor-made solutions for foreign companies looking to set up a new business, R&D or expand an existing one in Denmark. Please contact one of our experts here:

Copenhagen

  • Sarina Lohmann

    Title: Special Advisor – Maritime and transport – Analysis & Partnerships

    Area: Copenhagen

    Phone: +4533920423

Berlin

Kolding

Silkeborg

Aarhus

Aalborg

Oslo

London

Paris

Munich

New-York

Toronto

Silicon-Valley

Tokyo

Bangalore

Taipei

Shanghai

Singapore